{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=dcSSc&page=2", "query": { "condition": "dcSSc", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=dcSSc&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T19:46:51.858Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03919799", "title": "KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "System; Sclerosis", "Diffuse Cutaneous Systemic Sclerosis" ], "interventions": [ { "name": "Belumosudil (KD025)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kadmon, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 36, "start_date": "2019-06-26", "completion_date": "2023-02-17", "has_results": true, "last_update_posted_date": "2023-08-30", "last_synced_at": "2026-06-10T19:46:51.858Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03919799" }, { "nct_id": "NCT02465437", "title": "Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Cutaneous Systemic Sclerosis" ], "interventions": [ { "name": "JBT-101", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Part B Open-Label Extension", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corbus Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 42, "start_date": "2015-08", "completion_date": "2020-12-11", "has_results": true, "last_update_posted_date": "2021-04-21", "last_synced_at": "2026-06-10T19:46:51.858Z", "location_count": 9, "location_summary": "Los Angeles, California • Palo Alto, California • Baltimore, Maryland + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02465437" }, { "nct_id": "NCT04478994", "title": "A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Cutaneous Systemic Sclerosis" ], "interventions": [ { "name": "TEPEZZA", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 3, "start_date": "2021-11-17", "completion_date": "2022-12-08", "has_results": true, "last_update_posted_date": "2024-06-28", "last_synced_at": "2026-06-10T19:46:51.858Z", "location_count": 7, "location_summary": "Los Angeles, California • New Haven, Connecticut • Baltimore, Maryland + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04478994" }, { "nct_id": "NCT00879658", "title": "Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsing-remitting Multiple Sclerosis" ], "interventions": [ { "name": "BAF312", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 297, "start_date": "2009-03-30", "completion_date": "2011-05-04", "has_results": true, "last_update_posted_date": "2020-01-13", "last_synced_at": "2026-06-10T19:46:51.858Z", "location_count": 16, "location_summary": "Cullman, Alabama • San Francisco, California • Centennial, Colorado + 13 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Centennial", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Pompano Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00879658" }, { "nct_id": "NCT02588625", "title": "A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Scleroderma" ], "interventions": [ { "name": "BMS-986020", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2016-02", "completion_date": "2019-10", "has_results": false, "last_update_posted_date": "2016-07-22", "last_synced_at": "2026-06-10T19:46:51.858Z", "location_count": 19, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Stanford, California + 13 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02588625" }, { "nct_id": "NCT04138485", "title": "Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Cutaneous Systemic Sclerosis" ], "interventions": [ { "name": "IgPro10", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "CSL Behring", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-12-20", "completion_date": "2020-09-16", "has_results": false, "last_update_posted_date": "2020-11-17", "last_synced_at": "2026-06-10T19:46:51.858Z", "location_count": 20, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 15 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04138485" }, { "nct_id": "NCT00433186", "title": "Mycophenolate Mofetil in Systemic Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Cutaneous Systemic Sclerosis" ], "interventions": [ { "name": "Mycophenolate Mofetil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boston University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2006-03", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2011-03-31", "last_synced_at": "2026-06-10T19:46:51.858Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00433186" }, { "nct_id": "NCT07287670", "title": "EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Cutaneous Systemic Sclerosis" ], "interventions": [ { "name": "MTX-474", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Mediar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2026-04-16", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-06-10T19:46:51.858Z", "location_count": 6, "location_summary": "Newport Beach, California • Clearwater, Florida • Tampa, Florida + 3 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07287670" }, { "nct_id": "NCT00016458", "title": "Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Sclerosis" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "64 Years", "sex": "ALL", "summary": "Up to 64 Years" }, "enrollment_count": 20, "start_date": "2000-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2008-09-03", "last_synced_at": "2026-06-10T19:46:51.858Z", "location_count": 3, "location_summary": "Denver, Colorado • Durham, North Carolina • Seattle, Washington", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00016458" }, { "nct_id": "NCT02682511", "title": "Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Scleroderma, Diffuse", "Scleroderma, Systemic", "Scleroderma, Limited", "Sclerosis, Progressive Systemic", "Skin Diseases", "Connective Tissue Diseases", "Pathologic Processes", "Autoimmune Diseases" ], "interventions": [ { "name": "Oral Ifetroban", "type": "DRUG" }, { "name": "Oral Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cumberland Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 34, "start_date": "2017-01", "completion_date": "2026-08", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-06-10T19:46:51.858Z", "location_count": 10, "location_summary": "Tucson, Arizona • Los Angeles, California • Weston, Florida + 7 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Weston", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02682511" } ] }